[{"data":1,"prerenderedAt":165},["ShallowReactive",2],{"drug-fosaprepitant":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":21,"regimens":36,"contraindications":62,"warnings":72,"renal":86,"monitoring":87,"interactions":88,"review":89,"examples":92,"iran":98,"usApproval":105,"links":111,"populations":123},"fosaprepitant",1,{"fa":7,"en":8},"فوس‌آپری‌پیتانت","Fosaprepitant","alimentary-metabolism",{"fa":11,"en":12},"آنتاگونیست گیرنده NK1 (وریدی)","NK1 receptor antagonist (IV)",[14],{"name":15,"market":16},"Emend IV","US",[18,19,20],"emend iv","امند وریدی","فوزاپرپیتانت",[22],{"id":23,"form":24,"route":25,"label":26,"concentration":27,"markets":31,"refs":32},"vial-150","powder-for-injection","iv","150 mg vial",{"amount":28,"unit":29,"perUnit":30},150,"mg","vial",[16],[33],{"source":34,"section":35},"fda-fosaprepitant","3",[37],{"id":38,"disease":39,"label":40,"population":43,"type":47,"unit":29,"dose":48,"refs":49,"durationDays":52,"notes":53},"adult","cinv",{"fa":41,"en":42},"پیشگیری تهوع شیمی‌درمانی بزرگسال — ۱۵۰ mg وریدی روز ۱، انفوزیون ۲۰ تا ۳۰ دقیقه","CINV prevention, adults — 150 mg IV on day 1, infused over 20–30 min",{"minAge":44},{"value":45,"unit":46},18,"year","fixed",{"perDose":28,"dosesPerDay":5},[50],{"source":34,"section":51},"2.1",{"min":5,"max":5},[54],{"text":55,"refs":58},{"fa":56,"en":57},"انفوزیون حدود ۳۰ دقیقه پیش از شیمی‌درمانی تمام شود؛ همراه دگزامتازون و آنتاگونیست 5-HT3. کودک ۶ ماه تا ۱۷ سال (≥۶ kg) طبق جداول ۳ و ۴.","Finish about 30 min before chemotherapy; with dexamethasone and a 5-HT3 antagonist. Children 6 months–17 y (≥6 kg) per Tables 3 and 4.",[59,60],{"source":34,"section":51},{"source":34,"section":61},"2.2",[63],{"id":64,"severity":65,"text":66,"refs":69},"ci","block",{"fa":67,"en":68},"حساسیت به اجزای فرآورده؛ پیموزاید همزمان (QT).","Hypersensitivity to any component; concomitant pimozide (QT prolongation).",[70],{"source":34,"section":71},"4",[73,80],{"text":74,"refs":77},{"fa":75,"en":76},"تداخل مهم CYP3A4؛ کاهش INR با وارفارین (پایش ۷ تا ۱۰ روز)؛ کاهش اثر ضدبارداری هورمونی تا ۲۸ روز.","Clinically significant CYP3A4 interactions; decreased INR with warfarin (monitor days 7–10); reduced hormonal contraceptive efficacy for 28 days.",[78],{"source":34,"section":79},"5",{"text":81,"refs":84},{"fa":82,"en":83},"واکنش حساسیتی؛ واکنش محل انفوزیون.","Hypersensitivity reactions; infusion-site reactions.",[85],{"source":34,"section":79},[],[],[],{"status":90,"reviewer":91,"date":91},"unverified",null,[93],{"regimen":38,"formulation":23,"input":94,"expect":97},{"ageYears":95,"weightKg":96},50,70,{"perDose":28},{"status":99,"refs":100},"not-found",[101],{"source":102,"section":103,"url":104},"darooyab-generic","search","https:\u002F\u002Fwww.darooyab.ir\u002FSearch?q=Fosaprepitant",{"kind":106,"refs":107,"id":110},"ANDA",[108],{"source":34,"section":109},"SPL approval \u002F marketing category","ANDA210625",[112,115,119],{"kind":113,"url":114,"label":110},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=210625",{"kind":116,"url":117,"label":118},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=19919480-960b-4741-9611-c133d68512f5","FDA Fosaprepitant",{"kind":120,"url":121,"label":122},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa617042.html","Aprepitant\u002FFosaprepitant Injection",{"pregnancy":124,"lactation":133,"pediatric":141,"geriatric":149,"reproductive":157},{"level":125,"text":126,"quote":129,"refs":130},"caution",{"fa":127,"en":128},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary There are insufficient data on use of fosaprepitant in pregnant women to inform a drug associated risk.",[131],{"source":34,"section":132},"8.1",{"level":125,"text":134,"quote":137,"refs":138},{"fa":135,"en":136},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary Lactation studies have not been conducted to assess the presence of aprepitant in human milk, the effects on the breastfed infant, or the effects on milk production.",[139],{"source":34,"section":140},"8.2",{"level":125,"text":142,"quote":145,"refs":146},{"fa":143,"en":144},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","The safety and effectiveness of a single dose and a 3-day regimen of fosaprepitant have been established in pediatric patients 6 months to 17 years for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of HEC and MEC.",[147],{"source":34,"section":148},"8.4",{"level":125,"text":150,"quote":153,"refs":154},{"fa":151,"en":152},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","In general, use caution when dosing elderly patients as they have a greater frequency of decreased hepatic, renal or cardiac function and concomitant disease or other drug therapy [see Clinical Pharmacology (12.3) ].",[155],{"source":34,"section":156},"8.5",{"level":125,"text":158,"quote":161,"refs":162},{"fa":159,"en":160},"برچسب نکته‌ای درباره بارداری، پیشگیری یا باروری زنان و مردان دارد.","Label has advice on pregnancy testing, contraception or fertility for females and males.","Contraception Upon administration of fosaprepitant, the efficacy of hormonal contraceptives may be reduced.",[163],{"source":34,"section":164},"8.3",1792191545658]